Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A PHASE II TRIAL OF PF-04856884 (CVX-060), A SELECTIVE ANGIOPOIETIN-2 (ANG-2) INHIBITOR IN COMBINATION WITH AG-013736 (AXITINIB) IN PATIENTS WITH PREVIOUSLY TREATED METASTATIC RENAL CELL CARCINOMA

NCT01441414 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT01441414
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01441414 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A PHASE II TRIAL OF PF-04856884 (CVX-060), A SELECTIVE ANGIOPOIETIN-2 (ANG-2) INHIBITOR IN COMBINATION WITH AG-013736 (AXITINIB) IN PATIENTS WITH PREVIOUSLY TREATED METASTATIC RENAL CELL CARCINOMA
Lead sponsor
Pfizer
Phase
Phase 2
Overall status
Terminated
Start date
November 21, 2011
Completion date
March 27, 2014
Enrollment
18 (actual)
Sites
29

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic renal cell carcinoma